Alyeska Investment Group, L.P. Bluebird Bio, Inc. Transaction History

Alyeska Investment Group, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $5.15 Million - $9.9 Million	-5,656,565 Reduced 81.83%	1,255,937 $1.61 Million
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $9.12 Million - $33.4 Million	6,912,502 New	6,912,502 $9.54 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $7.38 Million - $12.5 Million	272,190 Added 14103.11%	274,120 $10.8 Million
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $2.45 Million - $3.96 Million	-38,029 Reduced 95.17%	1,930 $0
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $1.52 Million - $2.4 Million	-25,729 Reduced 39.17%	39,959 $3.96 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $4.75 Million - $6.08 Million	47,678 Added 264.73%	65,688 $10.3 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $1.46 Million - $2.35 Million	18,010	18,010 $3.21 Million

146

63.3M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $644M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.